The conversation discusses using oral castor oil as a hair growth stimulant for beard and scalp hair. One user questions its use, noting castor oil is typically a laxative in the Philippines.
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.
Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.
The user experienced hair thinning and used microneedling, DHT blocking shampoo, and Biotin DHT blocking oil to address it, avoiding finasteride and minoxidil unless necessary later. They reported mild improvement but received mixed feedback, with some suggesting other conditions or treatments like ciclopirox shampoo.
The user tried Minoxidil without success, and Finasteride worked but caused sexual side effects even at a very low dose. They are seeking alternative treatments for hair loss as they cannot tolerate anti-androgens and are also in therapy for mental health.
PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.
A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.